Logo

EDSA

Edesa Biotech, Inc.

EDSA

Edesa Biotech, Inc. • NASDAQ
$1.75 ▲ 2.34% (+0.04)
Market Cap $12.31 M
52w High $4.49
52w Low $1.55
Dividend Yield 0%
P/E -1.41
Volume 12.84K
Outstanding Shares 7.04M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.904M ▲ $-1.749M ▼ 0% $-0.25 ▲ $-1.695M ▼
Q2-2025 $0 $1.639M ▼ $-1.59M ▲ 0% $-0.3 ▲ $-1.565M ▲
Q1-2025 $0 $1.899M ▲ $-1.617M ▼ 0% $-0.48 ▼ $-1.574M ▼
Q4-2024 $0 $1.004M ▼ $-962.051K ▲ 0% $-0.3 ▲ $-917.844K ▲
Q3-2024 $0 $1.932M $-1.668M 0% $-0.52 $-1.617M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.362M ▼ $14.805M ▼ $672.674K ▼ $14.132M ▼
Q2-2025 $13.897M ▲ $16.454M ▲ $914.701K ▼ $15.54M ▲
Q1-2025 $1.564M ▲ $4.164M ▲ $1.9M ▲ $2.264M ▲
Q4-2024 $1.037M ▼ $3.814M ▼ $1.833M ▼ $1.981M ▼
Q3-2024 $2.041M $5.228M $2.361M $2.867M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.749M ▼ $-1.751M ▲ $0 $216.924K ▼ $-1.535M ▼ $-1.751M ▲
Q2-2025 $-1.59M ▲ $-2.333M ▼ $0 $14.773M ▲ $12.333M ▲ $-2.333M ▼
Q1-2025 $-1.617M ▼ $-1.517M ▼ $0 $2.072M ▲ $526.182K ▲ $-1.517M ▼
Q4-2024 $-962.051K ▲ $-967.039K ▼ $0 $-31.435K ▼ $-1.004M ▼ $-967.039K ▼
Q3-2024 $-1.668M $-856.479K $0 $106.025K $-758.747K $-856.479K

Revenue by Products

Product Q3-2018Q4-2018Q1-2019Q2-2019
Product
Product
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Edesa is still a pure R&D story with essentially no product revenue yet. Its income statement is dominated by research and operating expenses, which lead to ongoing losses each year. These losses are typical for a small clinical‑stage biotech but mean the company depends on outside funding rather than internal profits. Earnings per share have been negative and volatile, reflecting both the company’s spending and the impact of multiple reverse stock splits over time.

Balance Sheet

Balance Sheet The balance sheet is very light: modest total assets, largely in the form of cash, and effectively no traditional debt reported. That keeps financial leverage low but also highlights how limited the company’s resources are. Shareholders’ equity is small, which can magnify the impact of good or bad news. The history of repeated reverse splits suggests prior dilution and share price pressure, and it signals that preserving access to capital markets is critical for the company.

Cash Flow

Cash Flow Cash flows are driven by operating losses from research and corporate overhead, with cash consistently flowing out of the business and no meaningful offset from product sales. Capital spending needs are minimal, which is typical for a virtual or asset‑light biotech model. However, the pattern points to an ongoing need for fresh capital through equity, partnerships, or other financing, and future trial expansions or commercialization efforts would likely increase cash burn unless partnered.

Competitive Edge

Competitive Edge Edesa is a small player in a huge, competitive biotech space, but it is aiming at well‑defined, high‑need niches in inflammatory and immune diseases. The most important asset is its ARDS drug candidate, which has reported positive late‑stage trial results, potentially giving the company a foothold in a very serious condition with few effective treatments. Its focus on novel mechanisms and underserved indications offers differentiation, yet the firm still faces competition from much larger pharmaceutical companies, regulatory uncertainty, and the usual clinical risks. Its bargaining power and market reach will likely depend heavily on its ability to secure strong partners.

Innovation and R&D

Innovation and R&D Innovation is the core of Edesa’s value. The pipeline includes multiple first‑in‑class or highly differentiated candidates targeting key inflammatory pathways, with programs in acute respiratory distress syndrome, allergic contact dermatitis, vitiligo, and pulmonary fibrosis. The science focuses on upstream control of the immune response, which could translate into meaningful advantages if safety and efficacy hold up. Strong licensing arrangements and patent coverage support the IP position, but the portfolio is concentrated in a few related assets, so setbacks in any major program could materially affect perceived value. Progress from trials, regulatory feedback, and any partnering deals are the main markers of R&D success to watch.

Summary

Overall, Edesa is a high‑risk, high‑uncertainty clinical‑stage biotech with no current product revenue, ongoing losses, and a very lean balance sheet, but with a scientifically interesting pipeline anchored by a late‑stage ARDS candidate showing promising results. The company’s future hinges on three things: regulatory outcomes for its lead programs, its ability to translate clinical data into partnerships or commercial plans, and its capacity to keep funding R&D without overburdening shareholders. For anyone following the story, this is primarily a bet on the success and monetization of its core drug candidates rather than on existing financial strength or stable cash generation.

NEWS

October 31, 2025 · 4:30 PM UTC

Edesa Biotech Announces Upcoming Conference Schedule

Read more

October 28, 2025 · 7:45 AM UTC

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Read more